This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
All content for The Pharma Letter Podcast is the property of Simon Wentworth and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
A draft of the European Commission’s ongoing review of pharmaceutical legislation has leaked, prompting a bitterly-worded reaction from drugmakers, which accuse legislators of “sabotaging” the industry. There is no doubt that the proposals represent serious change. Maarten Meulenbelt, partner and expert on EU regulatory affairs at Sidley Austin, describes them as the most far-reaching for decades. On this week’s episode of The Pharma Letter Podcast, Mr Meulenbelt will walk us through...
The Pharma Letter Podcast
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
